source
- STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drugSTAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
- Vertex pays $28 million upfront to AbCellera for autoimmune T-cell engager collaborationVertex Pharmaceuticals has entered a collaboration with AbCellera, paying an upfront sum of $28 million to access the latter’s T-cell engager platform for autoimmune disease programs. Under the ag…